Lumida
/URGN
⌘K
Urogen Pharma Ltd

Urogen Pharma Ltd

URGN
$42.31USD↑+0.17%+0.07 today

MARKET CAP

2.1B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$42 – $44

52W RANGE

$16
$51

AI Summary

Stalk
Sell NowMedium

URGN has resumed a Stage 4 downtrend, driven by the Post-Parabola Collapse pattern and declining EMAs. Medium-term bias is bearish as price makes lower highs and lows and remains below the 9- and 20-day EMAs. Short-term momentum is negative, with price failing at near-term resistance and tracking lower. The momentum-oriented strategy favors continuation participation on rallies into the 9/20 EMA resistance zone (~44.8–45). Initiate Sell Now into that area and avoid chasing further declines.

  • ↑Q2 revenue forecast of $62.8M, marking sequential top-line growth
  • ↑EPS loss narrowing to $0.28 indicates improving financial momentum
  • ↓Sustained $0.28 EPS loss underscores persistent profitability challenges
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

UroGen Pharma Ltd. (Nasdaq: URGN) is an emerging biopharmaceutical company specializing in innovative therapies for urological cancers. It is significantly focused on the development and commercialization of new therapies, with its flagship product, ZUSDURI, addressing unmet needs in the treatment of upper urinary tract cancer. UroGen is positioned within the pharmaceutical sector's growth toward personalized medicine and novel treatment modalities, aiming for a substantial market presence as it capitalizes on the rising demand for targeted therapies.

Bull says

  • ↑Q2 revenue forecast of $62.8M, marking sequential top-line growth
  • ↑EPS loss narrowing to $0.28 indicates improving financial momentum
  • ↑Consensus price targets at $41–$44.75 imply ~16% upside
  • ↑Analysts raised EPS forecasts by 12.8% over last 60 days
  • ↑High earnings revision momentum and strong hedge-fund ownership support rally
  • ↑ZUSDURI’s niche in urological cancer taps significant unmet demand

Bear says

  • ↓Sustained $0.28 EPS loss underscores persistent profitability challenges
  • ↓Earnings yield lags sector peers, raising valuation concerns
  • ↓Elevated debt leverage increases cash-flow strain risk
  • ↓Stock declined 6.2% over two weeks on weak sentiment
  • ↓Competition from Merck, Pfizer and Astellas may erode pricing power
  • ↓Small market position adds vulnerability to regulatory shifts

Investment themes with URGN

Biotech↑ +0.07%

Genetic and drug innovations driving medical breakthroughs

ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-13-2025bullish

Transcript signals

Bull points

  • After receiving 6 weekly doses of JELMYTO, 41 of 71 patients in OLYMPUS achieved a complete response and their health outcomes were tracked for up to 12 months.
  • Revenue comprised of JELMYTO sales for the 3 months ended March 31, 2024, was $18.8 million compared with $17.2 million in the comparable period in 2023.
  • As we look ahead to 2024, we have several near-term catalysts, including the plan released of the 12-month duration of response data from the ENVISION study in June with our expected NDA submission this year.

Bear points

  • Cost of revenue was $1.7 million in the first quarter of 2024 compared with $2.3 million in the comparable period of 2023.
Read full transcript analysis ›